Adagio Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adagio Medical Holdings, Inc. (ADGM) on October 15, 2025, regarding events occurring on October 14, 2025. The Company, an emerging growth company incorporated in Delaware, operates in the medical device sector, specifically focusing on cryoablation systems. The filing details the entry into a material definitive agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company executed a Securities Purchase Agreement to raise capital through a private placement. Key financial terms include:
- Gross Proceeds: Approximately $19 million from the initial sale of shares and pre-funded warrants.
- Potential Future Proceeds: Up to approximately $31 million may be received upon the full cash exercise of Milestone Warrants.
- Securities Issued: 9,792,506 shares of Common Stock (or Pre-Funded Warrants) accompanied by Tranche A, B, and C Milestone Warrants.
- Warrant Structure: Each share is accompanied by three Milestone Warrants (Tranche A, B, and C), totaling 6,012,943 warrants per tranche.
- Purchase Price: The combined price per Share and accompanying Milestone Warrants is $1.9403. The combined price per Pre-Funded Warrant and accompanying Milestone Warrants is $1.9402.
- Exercise Price: Milestone Warrants are exercisable at $1.71 per share. Pre-Funded Warrants are exercisable at $0.0001 per share.
- Affiliate Participation: Entities affiliated with Perceptive Advisors LLC purchased securities for an aggregate price of $4,250,000.
Material Changes and Milestone Conditions
The transaction introduces significant contingent equity obligations tied to specific clinical and regulatory milestones. The Milestone Warrants expire upon the earlier of five years from issuance or 30 days following specific announcements:
- Tranche A: Announcement of results from the FULCRUM-VT IDE pivotal clinical trial.
- Tranche B: FDA approval of the vCLAS Cryoablation System.
- Tranche C: FDA approval of the second-generation vCLAS catheter system.
The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus prior periods, as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
Registration Rights: The Company agreed to file a registration statement for the resale of the securities within 45 days of the agreement date. Cash penalties apply for registration failures.
Ownership Caps: Holders are restricted from exercising warrants if it would result in ownership exceeding 4.99% (or up to 9.99% at option) of outstanding Common Stock, though this cap can be adjusted up to 19.99% with 61 days' notice.
Cashless Exercise: Holders may elect a cashless exercise for Milestone Warrants if no effective registration statement is available at the time of exercise.
Risks: The Company's ability to raise the full potential $31 million in future proceeds is contingent upon the successful achievement of clinical trial results and FDA approvals. Failure to meet these milestones or delays in regulatory approval could impact the Company's capital structure and liquidity.
Investor Verification Checklist
- Verify the exact number of shares issued as Common Stock versus Pre-Funded Warrants in the final closing documents.
- Confirm the status of the FULCRUM-VT IDE pivotal clinical trial and the timeline for result announcements.
- Review the Registration Rights Agreement for specific cash penalty amounts and timelines.
- Monitor the filing of the registration statement (S-1 or S-3) within the 45-day deadline to ensure liquidity for investors.
- Assess the dilution impact of the 18,038,829 total Milestone Warrants (6,012,943 x 3 tranches) if fully exercised.